Crohn’s disease: considerations for treatment choice during pregnancy
A. A. Markova,
E. I. Kashkina,
N. M. Nikitina,
I. V. Kozlova,
A. V. Aparkina,
D. A. Akhomgotova,
A. A. Babakhanova,
A. A. Astashkina https://doi.org/10.31146/1682-8658-ecg-244-12-135-141
Abstract
This article presents a clinical case of a pregnant patient with Crohn’s disease. When managing pregnant women with inflammatory bowel disease, the priority is maintaining disease remission using medications approved for use during pregnancy, including modern genetically engineered biological therapies, to preserve the health of both mother and fetus. In this case, the situation was complicated by a history of multiple surgeries and a functioning ileostomy. Collaborative care by a multidisciplinary team of specialists prevented complications and resulted in a successful pregnancy, delivery, and postpartum period.
About the Authors
A. A. Markova
Saratov State Medical University named after V.I. Razumovsky (Razumovsky University)
Russian Federation
Russian Federation
E. I. Kashkina
Saratov State Medical University named after V.I. Razumovsky (Razumovsky University)
Russian Federation
Russian Federation
N. M. Nikitina
Saratov State Medical University named after V.I. Razumovsky (Razumovsky University)
Russian Federation
Russian Federation
I. V. Kozlova
Saratov State Medical University named after V.I. Razumovsky (Razumovsky University)
Russian Federation
Russian Federation
A. V. Aparkina
Saratov State Medical University named after V.I. Razumovsky (Razumovsky University)
Russian Federation
Russian Federation
D. A. Akhomgotova
Saratov State Medical University named after V.I. Razumovsky (Razumovsky University)
Russian Federation
Russian Federation
A. A. Babakhanova
Saratov State Medical University named after V.I. Razumovsky (Razumovsky University)
Russian Federation
Russian Federation
A. A. Astashkina
State Healthcare Institution “Regional Clinical Hospital”
Russian Federation
Russian Federation
References
1. Shelygin Yu.A., Ivashkin V.T., Achkasov S.I. et al. Clinical guidelines. Crohn’s disease (К50), adults. Koloproktologia. 2023;22(3):10-49. (In Russ.) doi: 10.33878/2073-7556-2023-22-3-10-49.@@ Шелыгин Ю.А., Ивашкин В.Т., Ачкасов С.И. и др. Клинические рекомендации. Болезнь Крона (К50), взрослые. Колопроктология. 2023;22(3):1049. doi: 10.33878/2073-7556-2023-22-3-10-49.
2. McConnell R.A., Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am. 2016;45(2):285-301. doi: 10.1016/j.gtc.2016.02.006.
3. Dickson I. Pregnancy safe and beneficial for women with IBD. Nat Rev Gastroenterol Hepatol. 2019;16(8):454. doi: 10.1038/s41575-019-0182-2.
4. Eisfeld H., Glimm A.M., Burmester G.R. et al. Pregnancy outcome in women with different rheumatic diseases: a retrospective analysis. Scand J Rheumatol. 2021; Jul;50(4):299-306. doi: 10.1080/03009742.2020.1849788.
5. Rottenstreich A., Fridman Lev S., Rotem R. et al. Disease flare at prior pregnancy and disease activity at conception are important determinants of disease relapse at subsequent pregnancy in women with inflammatory bowel diseases. Arch Gynecol Obstet. 2020;301(6):1449-1454. doi: 10.1007/s00404-020-05557-8.
6. Mahadevan U., Robinson C., Bernasko N. et al. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156(5):1508-1524. doi: 10.1053/j.gastro.2018.12.022.
7. Uspenskaya Yu.B., Nanaeva B.A., Oleynik V.A. Conservative treatment of inflammatory bowel diseases during pregnancy. Review of current safety and efficacy data. Koloproktologia. 2023;22(1):147-159. (In Russ.) doi: 10.33878/2073-7556-2023-22-1-147-1@@ Успенская Ю.Б., Нанаева Б.А., Олейник В.А. Лекарственная терапия воспалительных заболеваний кишечника у беременных. Обзор актуальных данных по безопасности и эффективности. Колопроктология. 2023;22(1):147-159. doi: 10.33878/2073-7556-2023-22-1-147-15.
8. Nguyen J., Madonia V., Bland C.M. et al. A review of antibiotic safety in pregnancy-2025 update. Pharmacotherapy. 2025;45(4):227-237. doi: 10.1002/phar.70010.
9. Rüegg L., Pluma А., Hamroun S. et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. Ann Rheum Dis. 2025; Jun;84(6):910-926. doi: 10.1016/j.ard.2025.02.023.
10. Clowse M., Fischer-Betz R., Nelson-Piercy C. et al. Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol. Therapeutic Advances in Musculoskeletal Disease. 2022; Vol.14:1-18. doi: 10.1177/1759720X221087650.
11. Romanowska-Próchnicka K., Felis-Giemza A., Olesi ´nska M. et al. The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding.Int. J. Mol. Sci. 2021;22(6):2922. doi: 10.3390/ijms22062922.
Review
For citations:
Markova A.A., Kashkina E.I., Nikitina N.M., Kozlova I.V., Aparkina A.V., Akhomgotova D.A., Babakhanova A.A., Astashkina A.A. Crohn’s disease: considerations for treatment choice during pregnancy. Experimental and Clinical Gastroenterology. 2025;(12):135-141. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-244-12-135-141
Views:
498
JATS XML
Email this article 
